You are here

Articles

Posted on Saturday, April 11, 2020 - 1:35am
As the UK and the world see many more people test positive for COVID-19 You can help collect important data with this free symptom tracker by monitoring your day to day health and wellbeing.      &
Posted on Friday, April 3, 2020 - 2:59pm
It is important to note that the questions and answers below refer to chronic phase CML. Management of accelerated phase, blast crisis or post-transplant should be discussed in detail with the clinical team.
Posted on Monday, March 23, 2020 - 3:49pm
Expert Opinion from the NCRI CML Subgroup 17th Mar 2020, updated 27th March 2020 The latest UK government updates are listed here:
Posted on Sunday, March 22, 2020 - 5:04pm
This guidance is for people, including children, who are at very high risk of severe illness from coronavirus (COVID-19) because of an underlying health condition, and for their family, friends and carers.
Posted on Thursday, March 19, 2020 - 8:30pm
iCMLf only want to hear from patients who have had COVID-19 confirmed by a laboratory test.
Posted on Tuesday, March 10, 2020 - 3:22pm
THE NOVEL CORONAVIRUS AND THE COVID-19 DISEASE INFORMATION FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS From cml-foundation.org State of the Art as of 08 March 2020
Posted on Friday, February 28, 2020 - 11:40am
This NCCN QUICK GUIDE tm sheet summarises key points from the completeNCCN Guidelines for Patients®: Chronic Myeloid Leukemia. These guidelines explain
Posted on Wednesday, February 19, 2020 - 5:15pm
Thank you to everyone who completed our recent survey investigating App use and functionality in the setting of CML.
Posted on Monday, February 3, 2020 - 6:10pm
Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukaemia (CML).
Posted on Tuesday, January 14, 2020 - 4:46pm
Atypical CML, or aCML is a form of CML where there is no expression of the BCR-Abl fusion gene. This has made it difficult to treat.
Posted on Tuesday, November 5, 2019 - 9:30pm
An investigation into the use of app technology in patients with CML.
Posted on Thursday, October 3, 2019 - 12:50pm
Patients who maintained MR4.5 at 24 months of consolidation therapy proceeded to discontinuation of nilotinib.
Posted on Thursday, October 3, 2019 - 12:42pm
We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clinical isolates and cell lines.